Samsung Biologics announced on March 6 that it has entered into a contract manufacturing organization (CMO) production agreement valued at 381.9 billion won (US$287.0 million) with UCB, which is headquartered in Belgium. This agreement is an increase to the contract signed in 2017 with the company,
The 42nd JP Morgan Healthcare Conference is set to take place from Jan. 8 to 11 in San Francisco, California, in the U.S. This annual event, held every January, is renowned as the world’s largest healthcare investment venue where major global pharmaceutical companies, emerging biotech firms, and pro
Dong-A ST announced on Jan. 4 that it has signed a license-in agreement with SK Biopharmaceuticals to license out its new epilepsy drug Cenobamate in 30 countries including Korea, Southeast and Southwest Asia, Russia, Australia, New Zealand, and Turkiye.Under the agreement, Dong-A ST will receive dr
SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders and oncology, will present data on cenobamate at the American Epilepsy Society (AES) Annual Meeting, to be h
SK Inc. announced that its board of directors (BOD) held a meeting on July 26, in which the board declared to distribute an interim dividend of KRW 1,500 per share, matching last year’s payout. The total interim dividend payout amounts to approximately KRW 83.6 billion. SK Inc. has been distributing
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.Although SK Biopharm’s operating losses likely narrowed q-q in 2Q23, we believe that COGS-to-sales ratio returned to the previous high level, and SG&A expenses likely upped q-q on clinical costs. How
SK biopharmaceuticals has received Canadian market approval for its newly developed cenobamate epilepsy drug sold under the local product name Xcopri.On June 14, SK biopharmaceuticals announced that Health Canada had issued a Notice of Compliance for cenobamate, approving its application for market
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.SK Biopharm’s 1Q23 operating loss likely narrowed to W19.4bn. In 1Q23, US prescriptions for all third-gen epilepsy drugs grew the most rapidly in five years. Amid this market expansion, Xcopri saw its
Samsung Bioepis's biosimilar Renflexis, SK Biopharmaceuticals' epilepsy drug Xcopri, and Daewoong Pharmaceutical's botulinum toxin Nabota, are expected to exceed US$200 million in U.S. sales this year.The Renflexis sales added up to US$196 million last year. According to industry sources
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed.SK Biopharm posted 4Q22 sales of W62.8bn and an operating loss of W44.6bn, with operating income missing consensus on one-off factor (sales discounts). After the expiry of the patent for competing dru
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. SK Biopharm posted consolidated 3Q22 sales of W88.8bn and an operating loss of W9.2bn, beating consensus. The firm’s operating loss narrowed on the booking of W19.6bn in licensing out fees for Cenoba
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. We lower our TP on SK Biopharm to W120,000. Amid rising SG&A expenses, the US prescription growth rate for Xcopri has slowed. Moving ahead, the firm needs to deploy an aggressive market share expansi
SK Group announced on May 26 that it plans to invest 247 trillion won, 179 trillion won at home and the rest abroad, for the next five years, focusing on the so-called BBC industries -- batteries, biotech and chips.SK Group decided to invest more than half of the total investment, 142 trillion won,
SK Biopharmaceuticals announced on Dec. 23 that it has licensed out Cenobamate technology to Endo International, a specialty pharmaceutical company based in Dublin, Ireland.Cenobamate is a medication used for the treatment of partial-onset seizures, a kind of epilepsy. It is sold under the brand nam
KT announced on Dec. 8 that it will invest US$5 million in series A financing of NeuroSigma, a U.S. electronic drug developer.KT signed a business agreement with NeuroSigma in June and began cooperation in product development and commercialization in the field of electronic medicine. With this equit
SK Biopharmaceuticals was recently sued for damages by a partner who hold the European sales rights to its own new drug, cenobamate, which is sold under the brand names Xcopri (U.S.) and Ontozry (EU). It is a medication used for the treatment of partial-onset seizures, a kind of epilepsy, in adults.
Cerecin Inc., a clinical-stage biotechnology company pioneering innovative neurotherapeutics, announced on Oct. 19 that it has raised US$40 million in an oversubscribed round of financing. A Series II investment was initially made by long-term investor, Nestle. In follow up to this round, Series IIA
The U.S. Food and Drug Administration is expected to conduct due diligence on Hanmi Pharmaceutical's plant in Pyeongtaek sometime in May. The FDA will inspect the production facilities for Hanmi’s neutrophilia drug Rolontis. Originally scheduled for October 2020, the due diligence was postponed
SK Biopharm has licensed out its new drug Cenobamate, which has been approved by the U.S. Food and Drug Administration (FDA), to a Japanese company.The company announced on Oct. 13 that it has signed a deal with Ono Pharmaceutical of Japan to hand over the right to develop and commercialize Cenobama
SK Biopharm will begin clinical trials of Cenobamate (U.S. product name: Xcopri), a new epilepsy treatment, in Asia.SK Biopharm announced on Sept. 10 that the Korean Ministry of Food and Drug Safety approved its investigational new drug application (IND) on Sept. 9. The company is waiting for approv